By Luke Piggott (Principal Scientist - Debiopharm)2025-03-25T11:13:10
As cancer therapies evolve, a critical opportunity is emerging in the form of DNA Damage Response (DDR) research. With breakthroughs in genomics, drug delivery and AI, DDR pathways are set to overcome resistance and alter treatment strategies. Find out why now is the perfect moment to refocus on DDR, and ...
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-30T09:54:00Z
2026-03-27T13:06:00Z
2023-03-08T16:29:20
Sponsored by Bio-Techne
2024-02-08T11:07:39
Sponsored by Samplix ApS
2025-09-24T14:00:00
Sponsored by Eurofins Discovery
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2023-09-27T13:56:39
Sponsored by Euretos
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
Site powered by Webvision Cloud